Physicians may legitimately use drugs in ways that the FDA did not approve. However, sale representatives may not discuss these off-label uses directly with physicians, no matter how well accepted the uses may be in practice. Since off-label prescriptions may account for a large percentage of a drug’s sales, representatives must understand how to navigate this topic of discussion in a compliant manner.
This module covers the rules around discussing off-label uses, including the high consequences of non-compliance, such as a recent $430 million penalty for one drug company. It includes practical selling tips and case studies to help reps understand the compliance challenges they face when selling to physicians.
To find about each course in our compliance curriculum, click on one of the topics shown or click the button below to view a sample course.
This module covers the rules around discussing off-label uses, including the high consequences of non-compliance, such as a recent $430 million penalty for one drug company. It includes practical selling tips and case studies to help reps understand the compliance challenges they face when selling to physicians.
